BioSpace News Archive

Cold Spring Harbor Laboratory welcomes photographer and public health advocate Jeanne Moutoussamy-Ashe to its board of trustees.

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the 31st Annual Oppenheimer Healthcare Conference on Tuesday, March 16, 2021 at 1:50 PM Eastern Time.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the closing of its underwritten public offering of 5,175,000 shares of its common stock at a public offering price of $31.00 per share, which includes 675,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock.

Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it is offering to sell shares of its common stock in an underwritten public offering.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Oppenheimer 31st Annual Healthcare Conference at 4:30 p.m. Eastern Time on Tuesday Mar. 16, 2021.

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical stage company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today reported financial results for fourth quarter and full year 2020 and provided a business update.

Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology, announced today the planned resubmission of two investigational new drug (IND) applications with the U.S. Food and Drug Administration (FDA)

Libervant™ (diazepam) Buccal Film New Drug Application (NDA) resubmission expected end of second quarter 2021 Epinephrine program and development strategy to be highlighted at a virtual investor event to be held at 9:00 a.m. ET on March 25, 2021 Entered U.S. licensing and supply agreement for Riluzole Oral Film for treatment of ALS with Mitsubishi Tanabe Pharma America Sympazan ® (clobazam) continues to meet key performance metrics Management to host conference call and webcast at 8:00 a.m

Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that it has priced an underwritten public offering of 5,000,000 shares of common stock at a public offering price of $11.25 per share, which would result in gross proceeds of approximately $56.25 million, before underwriting discounts and commissions.